The impact of export regulations on recombinant viral vaccine development for emerging infectious diseases.

Wolf, Jayanthi; Hansen, Ryan; Hassis, Kimberly; Lapps, William; Warmuth, Emese

Wolf, Jayanthi; Hansen, Ryan; Hassis, Kimberly; Lapps, William; Warmuth, Emese.

Wolf J; Merck & Co., Inc., Kenilworth, NJ, USA. Electronic address: Jayanthi_Wolf@merck.com.
Hansen R; Merck & Co., Inc., Kenilworth, NJ, USA.
Hassis K; Merck & Co., Inc., Kenilworth, NJ, USA.
Lapps W; Merck & Co., Inc., Kenilworth, NJ, USA.
Warmuth E; MSD Pharma Hungary Kft, Budapest, Hungary.

Vaccine ; 38(46): 7198-7200, 2020 10 27.

Article in English | MEDLINE | ID: covidwho-813891

Subject(s)

Commerce/legislation & jurisprudence; Communicable Diseases, Emerging/prevention & control; Viral Vaccines/immunology; Virus Diseases/prevention & control; Betacoronavirus/immunology; COVID-19; Coronavirus Infections/prevention & control; Ebolavirus/immunology; Hemorrhagic Fever, Ebola/prevention & control; Humans; Pandemics/prevention & control; Pneumonia, Viral/prevention & control; SARS-CoV-2

Keywords

Ebola; Export; Regulations; SARS-CoV-2; Vaccines

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Virus Diseases / Viral Vaccines / Commerce / Communicable Diseases, Emerging Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Vaccine Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google